calendar
93 catalysts · 69 phase readout · 24 8k filing · 4 earnings
next 91 dayslessmore
MonWedFri
93 catalysts · 69 phase readout · 24 8k filing · 4 earnings
Items: 5.07
Items: 5.07
Items: 5.07
Items: 5.07
Items: 4.01, 9.01
Items: 5.02, 7.01, 8.01, 9.01
Items: 1.01, 3.02, 7.01
Items: 1.01, 8.01, 9.01
Items: 2.02, 9.01
Items: 5.02
Items: 8.01, 9.01
Items: 2.02, 9.01
Items: 2.02, 9.01
Items: 2.02, 8.01, 9.01
Items: 2.02, 9.01
Items: 2.02, 9.01
Items: 5.02, 9.01
Items: 2.02, 9.01
Items: 2.02
Items: 2.02, 9.01
Items: 2.02, 9.01
Items: 7.01, 8.01, 9.01
Items: 1.01, 1.02, 2.03, 9.01
Items: 8.01, 9.01
Sponsor: Eastern Cooperative Oncology Group. Phase: PHASE2. Conditions: T-cell Acute Lymphoblastic Leukemia
Sponsor: Institute of Oncology Ljubljana. Phase: NA. Conditions: Chronic Intestinal Failure, Intestinal Failure, Home Parenteral Nutrition
Sponsor: Institute of Oncology Ljubljana. Phase: NA. Conditions: Cancer Pain, Neoplasm-Related Pain
Sponsor: Dr. Mark Mulder. Phase: . Conditions: Cancer-related Pain, Pain Assessment, Artificial Intelligence (AI), Oncology, Oncology Pain, Database, Facial Expression, Voice, Cancer
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Phase: . Conditions: Postoperative Pulmonary Complications (PPCs), Abdominal Surgeries, Postoperative Pain Management
Sponsor: Institute of Oncology Ljubljana. Phase: NA. Conditions: Gynecologic Cancer, Urologic Cancer, Breast Cancer
Sponsor: French Africa Pediatric Oncology Group. Phase: . Conditions: Staging, Therapeutic Recommendations
Sponsor: Centre Hospitalier Universitaire Dijon. Phase: PHASE3. Conditions: Elective Surgery for Any Digestive Cancer
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Phase: . Conditions: Neoplasms, Postoperative Complications, Perioperative/Postoperative Complications, Intensive Care Units
Sponsor: Eastern Cooperative Oncology Group. Phase: PHASE3. Conditions: Head and Neck Cancer
Sponsor: Azienda USL Reggio Emilia - IRCCS. Phase: NA. Conditions: Professional Quality of Life, Palliative Care, Oncology
Sponsor: Alliance for Clinical Trials in Oncology. Phase: PHASE2. Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Sponsor: Institute of Oncology Ljubljana. Phase: NA. Conditions: Head and Neck Cancer
Sponsor: Société des Produits Nestlé (SPN). Phase: NA. Conditions: Cerebral Palsy (CP), Oncology
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Phase: . Conditions: Breast Cancer, Mastectomy, Postoperative Pain, Analgesic Use
Sponsor: National Cancer Institute (NCI). Phase: . Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer
Sponsor: Radionetics Oncology. Phase: PHASE1. Conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer
Sponsor: Loxo Oncology, Inc.. Phase: PHASE3. Conditions: Lymphoma, Mantle-Cell
Sponsor: University of Salamanca. Phase: NA. Conditions: Oncology, Chemotherapy-Induced Peripheral Neuropathy
Sponsor: Johannes Gutenberg University Mainz. Phase: NA. Conditions: Pediatric Oncology
Sponsor: NRG Oncology. Phase: PHASE2. Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Sponsor: Children's Oncology Group. Phase: PHASE3. Conditions: Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Sponsor: Nested Therapeutics, Inc. Phase: PHASE1. Conditions: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
Sponsor: Centre Hospitalier Universitaire de Nīmes. Phase: . Conditions: Cancer
Sponsor: Institute of Oncology Ljubljana. Phase: PHASE4. Conditions: Breast Cancer, Adherence, Medication
Sponsor: NRG Oncology. Phase: PHASE1. Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma, Squamous Cell Cancer